Kurtipek Ercan, Bekci Taha Tahir, Kesli Recep, Sami Said Sami, Terzi Yuksel
Department of Chest Diseases, Konya Training and Research Hospital, Konya, Turkey.
Department of Clinical Microbiology, Konya Training and Research Hospital, Konya, Turkey.
J Pak Med Assoc. 2015 Dec;65(12):1283-7.
To investigate whether neutrophil-lymphocyte ratio and platelet-lymphocyte ratio like C-reactive protein can be used as markers of acute exacerbation in chronic obstructive pulmonary disease.
The cross-sectional study was conducted at Konya Training and Research Hospital, Konya, Turkey, between December 2012 and April 2013, and comprised patients with stable and acute chronic obstructive pulmonary disease. All participants were male and aged >40 years. Patients were included prospectively from outpatient and emergency units according to recent Initiative for Chronic Obstructive Lung Disease 2013 criteria. C-reactive protein, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio of each group were measured and compared.
Of the 94 patients, 48(51%) had stable disease with a mean age of 66.65±10.17 years (range: 49-79 years), and 46(49%) had acute exacerbation with a mean age of 62.67±9.41 years (range: 48-92 years). Mean levels of C-reactive protein, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were 5.04±6.65, 2.75±1.11 and 137.39±65.42 for stable disease, and 57.68±58.49, 7.99±5.72 and 231.18±141.36 for those with acute exacerbation (p=0.001). Cut-off values were neutrophil-lymphocyte ratio =3.3, platelet-lymphocyte ratio =150, and C-reactive protein =5 mg/dl. Positive predictive values for C-reactive protein, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were determined as 82% (odds ratio: 27.4); 85% (odds ratio: 32.5); and 73% (odds ratio: 6.3) . Receiver-operating characteristic curve showed a significantly more area under curve of neutrophil-lymphocyte ratio (0.88) compared to platelet-lymphocyte ratio (0.74) (p<0.05).
During acute exacerbations of chronic obstructive pulmonary disease, neutrophil-lymphocyte ratio may be used as an easily measurable, available and cost-effective parameter with high prognostic accuracy in clinical practice.
探讨中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值是否能像C反应蛋白一样作为慢性阻塞性肺疾病急性加重的标志物。
2012年12月至2013年4月在土耳其科尼亚培训与研究医院进行了一项横断面研究,纳入了稳定期和急性加重期慢性阻塞性肺疾病患者。所有参与者均为男性,年龄>40岁。根据最新的2013年慢性阻塞性肺疾病倡议标准,前瞻性地从门诊和急诊科室纳入患者。测量并比较每组患者的C反应蛋白、中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值。
94例患者中,48例(51%)病情稳定,平均年龄为66.65±10.17岁(范围:49 - 79岁),46例(49%)为急性加重期,平均年龄为62.67±9.41岁(范围:48 - 92岁)。稳定期患者C反应蛋白、中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值的平均水平分别为5.04±6.65、2.75±1.11和137.39±65.42,急性加重期患者分别为57.68±58.49、7.99±5.72和231.18±141.36(p = 0.001)。截断值分别为中性粒细胞与淋巴细胞比值 = 3.3、血小板与淋巴细胞比值 = 150及C反应蛋白 = 5mg/dl。C反应蛋白、中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值的阳性预测值分别确定为82%(比值比:27.4);85%(比值比:3.5);73%(比值比:6.3)。受试者工作特征曲线显示,中性粒细胞与淋巴细胞比值的曲线下面积(0.88)显著大于血小板与淋巴细胞比值的曲线下面积(0.74)(p<0.05)。
在慢性阻塞性肺疾病急性加重期,中性粒细胞与淋巴细胞比值在临床实践中可作为一种易于测量、可得且具有成本效益的参数,具有较高的预后准确性。